Feb 27 |
Alector Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
|
Feb 26 |
Alector FY 2023 Earnings Preview
|
Feb 20 |
Alector to Host Fourth Quarter and Full-Year 2023 Earnings Call
|
Feb 20 |
Earnings Preview: Alector (ALEC) Q4 Earnings Expected to Decline
|
Feb 8 |
Alector Announces First Patient Dosed in PROGRESS-AD Phase 2 Clinical Trial of AL101/GSK4527226 in Patients with Early Alzheimer’s Disease
|
Feb 8 |
Strength Seen in Alector (ALEC): Can Its 6.0% Jump Turn into More Strength?
|
Feb 7 |
GSK/Alector win FDA breakthrough tag for dementia therapy
|
Feb 7 |
FDA Grants Latozinemab Breakthrough Therapy Designation for Frontotemporal Dementia Due to a Progranulin Gene Mutation (FTD-GRN)
|
Feb 1 |
With 67% institutional ownership, Alector, Inc. (NASDAQ:ALEC) is a favorite amongst the big guns
|
Jan 25 |
Alector (ALEC) Upgraded to Strong Buy: Here's What You Should Know
|